CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle Disorders CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle D

Global Urea Cycle Disorders Treatment Market to Surpass US$ 1,510.2 Million by 2027, Says Coherent Market Insights (CMI) SEATTLE, May 25, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global urea cycle disorders treatment market is estimated to be valued at US$ 1,188.9 million in 2020 and is...